Article
Increased risk of late-onset, immune-mediated, adverse reactions related to dermal fillers in patients bearing HLA-B*08 and DRB1*03 haplotypes.
Dermatologic therapy - 1 Jan 2021
Decates Tom S, Velthuis Peter J, Schelke Leonie W, Lardy Neubury, Palou Eduard, Schwartz Simo, Bachour Yara, Niessen Frank B, Nijsten Tamar, Alijotas-Reig Jaume
Abstract excerpt
Even though manufacturers claim that the dermal fillers are nontoxic and nonimmunogenic, adverse events may occur. Clinically and histologically, most of the late onset adverse events present as an inflammatory response. To assess whether HLA polymorphisms are associated with late-onset inflammatory adverse events related to dermal fillers. A total of 211 patients were included, of whom 129 experienced late-onset...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.